Compugen Ltd (CGEN) stock

CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026Score 12/30

$2.10−0.02 (-0.94%)

Close on Nov 13, 2026Market cap $198.56MP/E 5.5Yield –

Compugen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Compugen has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CGEN.

Revenue growth161.1% · median -54.0%

Gross margin87.3% · median 39.5%

Operating margin43.1% · median -252.3%

Net margin48.6% · median -260.8%

Advertisement
300 × 250

See a number that looks wrong?